Genocea Biosciences, which develops novel vaccines for infectious diseases through T cell immune responses, raised $66 million by offering 5.5 million shares at $12, at the low end of the range of $12 to $14. Genocea Biosciences plans to list on the NASDAQ under the symbol GNCA. Citi and Cowen were the lead managers on the deal.
